Aquaporin-1 gene therapy as a novel method to treat radiation-induced salivary gland damage: The case for adeno-associated virus vectors.
Gene therapy research offers a potential disease-modifying approach to radiation-damaged salivary glands, a long-standing problem for cancer survivors.
Radiation-induced xerostomia affects hundreds of thousands of head-and-neck cancer survivors with no approved disease-modifying treatment beyond palliative measures. This review in Oral Oncology synthesizes preclinical AAV-AQP1 gene therapy evidence and argues for a clinical translation pathway, particularly using improved AAV vector designs.
What the study was
- Study design
- review
- Population
- Head-and-neck cancer survivors with radiation-induced xerostomia
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Oral Oncol
Why it surfaced
Standard: novel gene therapy approach for a high-prevalence oncology complication; small author team limits scope; review design with preclinical evidence only limits clinical readiness; relevant to gene therapy and rare disease unmet need watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.